Keryx Biopharmaceuticals , Inc. (NASDAQ: KERX ) Q2 2014 Results Earnings Conference Call August 07, 2014, 08:00 AM ET Executives Amy B. Sullivan - VP, Corporate Development
Keryx Biopharmaceuticals ( KERX +1.2% ) Q2 results : Revenues: $0; Operating Expenses: $22.5M (+95.6%); Operating Loss: ($22.5M) (-95
The following audio is from a conference call that will begin on August 07, 2014 at 08:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
By Alexander Maxwell : It can be very hard for investors to be able to keep track of all of the different events going on within the biotech world, with clinical trial results, and FDA decisions happening rather frequently. The purpose of this article is to hopefully make investor's lives a little
By Zvi Bar : Keryx Biopharmaceuticals (NASDAQ: KERX ) has a very good chance of getting its phosphate binder, Zerenex, approved by the FDA in early September. If this does occur
July 24 (Reuters) - A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday.
(Reuters) - Keryx Biopharmaceuticals Inc's kidney drug proved effective in treating chronic kidney disease patients not on dialysis, sending the company's shares to a seven-year high on hopes the...
(Reuters) - Keryx Biopharmaceuticals Inc and Aeterna Zentaris said their experimental colorectal cancer drug did not meet the main goal of a late-stage trial, raising doubts on the drug's future as a...
We are no longer providing equity research on Keryx Biopharmaceuticals KERX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
We are putting our fair value estimate for Keryx Biopharmaceuticals KERX under review after the company released positive Phase II clinical trial data on KRX-0401 (perifosine) when used to treat advance